| General Information of Drug Metabolite (DM) (ID: DM005057) |
| DM Name |
Finerenone M13 Metabolite
|
|
|
|
|
|
|
|
| Full List of Drug-Metabolizing Enzyme (DME) Related to This DM |
| DME(s) Producing This DM through Metabolism |
| DME Name |
DME ID |
Reactant |
Reaction |
Related Drug |
REF |
|
Cytochrome P450 3A4 (CYP3A4)
|
DME0001
|
| Oxidation - O-deethylation |
Finerenone
|
[1] , [2] |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Full List of Drug(s) That Produce This DM By Metabolism |
| Finerenone |
DR3519
|
Phase 3 |
Diabetic nephropathy |
|
|
| References |
| 1 |
Biotransformation of Finerenone, a Novel Nonsteroidal Mineralocorticoid Receptor Antagonist, in Dogs, Rats, and Humans, In Vivo and In Vitro
|
| 2 |
Aldosterone and Mineralocorticoid Receptor Signaling as Determinants of Cardiovascular and Renal Injury: From Hans Selye to the Present
|
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.
